Vertex announces reimbursement of ORKAMBI and SYMDEKO in Australia
Category: #health  By Pankaj Singh  Date: 2019-10-21
  • share
  • Twitter
  • Facebook
  • LinkedIn

Vertex announces reimbursement of ORKAMBI and SYMDEKO in Australia

Vertex Pharmaceuticals Inc. is a global biopharmaceutical company that is relentless in striving for medical excellence while developing transformative therapies for life-threatening and serious diseases, such as cystic fibrosis. It has made a name for itself by investing in various scientific innovations.

However, recently the firm made headlines when it announced that SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) will be reimbursed in Australia for people suffering from CF (cystic fibrosis) that are homozygous for the F508del mutation or who have an instance of the F508del mutation along with a different responsive RF (residual function) mutation in the CFTR gene.

Reportedly, patients with the second condition would be able to obtain medicine for their cause for the first time. Moreover, ORKAMBI® (lumacaftor/ivacaftor) will be reimbursed to children suffering from CF between the ages 2 to 5 and those who have dual copies of the F508del mutation in their CFTR gene. People above 6 years already have access to ORKAMBI® since October 2018 in Australia.

Speaking on the move, Ludovic Fenaux, Senior Vice President, Vertex International, said that the company is pleased to share that ORKAMBI® and SYMDEKO® will become immediately accessible to patients with cystic fibrosis in Australia.

Moreover, the company appreciates PBAC (Pharmaceutical Benefits Advisory Committee) for recognizing the worth of these drugs to patients and the company extends its appreciation to the Minister for Health and the Department of Health in Australia for their solid collaboration and engagement to complete the agreement, cites Fenaux.

However, this news comes at the heels of recent management change in the company. Earlier this year, Vertex had revealed that Carmen Bozic, M.D., would serve as the firm’s Executive Vice President of Global Medical Affairs and Medicines Development.

Additionally, Dr. Bozic will fulfill the additional role of Chief Medical Officer (CMO), as the current CMO Reshma Kewalramani takes up the position of President and Chief Executive Officer.

Source Credit: https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-reimbursement-cystic-fibrosis-medicines



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Yahoo Japan explores plans for a merger with Navers Line app
Yahoo Japan explores plans for a merger with Navers Line app
By Pankaj Singh

Yahoo! Japan Corp., a Japanese internet firm, has recently cleared the fog on its merger with trending messaging app Line. According to reports, the merger would see the formation of a new internet group that would cov...

Skyroam Solis X launched online for purchase or rental options
Skyroam Solis X launched online for purchase or rental options
By Pankaj Singh

In this era of smart technologies and digitalization, the need for high speed internet connectivity have been doing rounds globally. To suffice these requirements, Skyroam Hotspot has taken a step forward to equip its ...

Spell & The Gypsy Collective rolled out on Workarea Commerce Cloud
Spell & The Gypsy Collective rolled out on Workarea Commerce Cloud
By Pankaj Singh

Workarea Commerce, a renowned commerce platform for new merchants across various sectors, and Syatt Media, a Canada based e-commerce agency with deep platform and industry expertise, announced that Spell & The Gyps...